IL17RB and breast carcinoma: This effect was hypothesized to be due to the increased levels of IL-25 receptor (IL-17RB) expressed in malignant tumor cells, which correlates with previous findings associating low levels of IL-17RB with aggressive breast cancers and decreased overall survival10, 11.